Mr. Wenjie Zhang is the Chairman, Executive Director, and Chief Executive Officer of Henlius. Mr. Zhang has nearly 30 years of operational experience in the pharmaceutical industry.
Before joining Henlius in March 2019, Mr. Zhang served as General Manager of Amgen China where he was leading the company’s overall efforts in expanding the business into the Chinese market. During his tenure as General Manager, Amgen China has effectively built up its commercial infrastructure, organization, and competency. He successfully launched Repatha® (evolocumab), Amgen’s first product in China. Prior to that, Mr. Zhang was the Executive Director, Marketing for Amgen Japan and Asia Pacific region, responsible for marketing and business development in China, Japan, Australia and other Asia Pacific countries and regions.
Prior to Amgen, Mr. Zhang worked as Vice President, Oncology for Roche China from 2010 to 2014, where he significantly grew the Roche oncology portfolio including Avastin® (bevacizumab), Tarceva®(erlotinib) and MabThera® (rituximab) in the China market. He also led Roche China oncology franchise in pipeline planning, franchise strategy, and franchise marketing.
Before then, Mr. Zhang served as the Head of Business Development at Bayer Schering Pharma, Asia Pacific Headquarters, Product Manager of US Marketing, Business Development Manager and Deputy Director of Global Marketing at Bayer Pharmaceuticals USA. In this role, he led the fastest-growing business unit within Bayer China. He also had dual responsibility as Head of the same business unit for the Asia Pacific region. He succeeded in launching multiple products in China including Nexavar®, Kogenate® and Betaferon®.
Mr. Zhang holds an MBA degree from Yale University and a B.S. degree in microbiology from Shandong University.